Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study.
Here, we present the fi nal analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events).PDF
Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer.
We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castrationresistant prostate cancer who have received chemotherapy.PDF
The combination of the mTOR inhibitor everolimus with the aromatase inhibitor exemestane was evaluated in the randomized Phase III BOLERO-2 trial.
Research has indicated that aberrant signaling through the mTOR pathway is associated with resistance to endocrine therapies.PDF
Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resistance to endocrine therapy results in disease progression in a large proportion of breast cancers.
Through the understanding of the mechanisms of endocrine resistance, identification of implicated pathways and targets has led to the development of novel agents targeting these pathways.PDF